欧洲医学肿瘤学会（ESMO）关于子宫内膜癌患者的诊断、治疗和随访的最新临床实践指南于2022年出版。因此，ESMO和印度医学与儿科肿瘤学会（ISMPO）决定在2022年7月召开虚拟会议，以适应亚洲地区子宫内膜癌管理的差异，以制定ESMO 2022指南。这些指南代表了来自中国（CSCO）、印度（ISMPO）、印尼（ISHMO）、日本（JSMO）、韩国（KSMO）、马来西亚（MOS）、菲律宾（PSMO）、新加坡（SSO）、台湾（TOS）和泰国（TSCO）的亚洲专家团体共识意见。投票是基于科学证据，独立于不同亚洲国家当前的治疗实践和治疗可及性限制，针对适当情况进行讨论。本指南手稿的目的是提供指导，以优化和协调在不同亚洲地区对患有子宫内膜癌的患者的管理。其依据西方和亚洲试验提供的证据，同时尊重临床表现的差异，包括分子分型和治疗选择不足的差异，包括药物获批和偿付策略。版权所有 © 2022作者。由Elsevier Ltd.出版。保留所有权利。

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer was published in 2022. It was therefore decided, by both the ESMO and the Indian Society of Medical and Paediatric Oncology (ISMPO), to convene a virtual meeting in July 2022 to adapt the ESMO 2022 guidelines to take into account the variations in the management of endometrial cancer in Asia. These guidelines represent the consensus opinion of a panel of Asian experts representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). Voting was based on scientific evidence and was conducted independently of the current treatment practices and treatment access constraints in the different Asian countries, which were discussed when appropriate. The aim of this guideline manuscript is to provide guidance for the optimisation and harmonisation of the management of patients with endometrial cancer across the different regions of Asia, drawing on the evidence provided by Western and Asian trials whilst respecting the variations in clinical presentation, diagnostic practices including molecular profiling and disparities in access to therapeutic options, including drug approvals and reimbursement strategies.Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.